Burkholderia Cepacia: An Emerging Superbug in Intensive Care Unit Settings of Tertiary Care Hospitals in Pakistan
Abstract
Objective: To determine the frequency, risk factors, and antibiotic susceptibility pattern of Burkholderia cepacia isolates from clinical specimens in a Pakistani tertiary care hospital. Study Design: Cross-sectional Study Place and Duration of Study: Department of Microbiology, Armed Forces Institute of Pathology, Rawalpindi Pakistan, from Jul 2017 to Jun 2021. Methodology: The Burkholderia cepacia strains were isolated from clinical samples by routine microbiological methods. In our laboratory, the identification and antimicrobial susceptibility testing of the isolate were made by API 20NE and VITEK-2 Automated Microbiology Analyzer. Results: Four hundred and nineteen (419) str5-ains of Burkholderia cepacia were isolated during the study period. Among them,277(66.1%) and 57(13.6%) isolates were from blood cultures and lower respiratory tracts, respectively. The antibiotic-resistant rates of the isolates of Minocycline, Cotrimoxazole, Levofloxacin, Meropenem, and Ceftazidime were 13(3.1%), 26(6.2%), 49(11.6%),74(17.6%) and 118(28.16%) respectively. Conclusion: We observed a gradual increase in the frequency of isolation. A surge in antimicrobial resistance was also seen during the study period underscoring the need for rigorous implementation of antimicrobial stewardship programs and infection control practices.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing
- Laboratory-based nationwide surveillance of antimicrobial resistance in Ghana
- Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains
- Incidence and factors associated with development of phlebitis: results of a pilot study cohort
- Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori
- Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.